Evercore ISI initiated coverage of Damora Therapeutics (DMRA) with an Outperform rating and $46 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMRA:
- Damora Therapeutics Announces Major Leadership and Board Overhaul
- Damora names Peter Harwin chairman, appoints Spyre Therapeutics CEO to board
- Damora Therapeutics appoints Jennifer Jarrett as CEO
- Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway